A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells
作者： Shibashish Giri , Augustinus Bader
DOI: 10.1016/J.DRUDIS.2014.10.011
关键词:
摘要: Knockout, knock-in and conditional mutant gene-targeted mice are routinely used for disease modeling in the drug discovery process, but human response is often difficult to predict from these models. It believed that patient-derived induced pluripotent stem cells (iPSCs) could replace millions of animals currently sacrificed preclinical testing provide a route new safer pharmaceutical products. In this review, we discuss use IPSCs process. We highlight how they can be assess toxicity clinical efficacy candidates before latter moved into costly lengthy trials.
elsevier.com
sci-hub.se 参考文章(107)
Jorge J. Asconapé, Use of antiepileptic drugs in hepatic and renal disease. Handbook of Clinical Neurology. ,vol. 119, pp. 417- 432 ,(2014) , 10.1016/B978-0-7020-4086-3.00027-8
Giorgio Minotti, Cardiotoxicity of Non-Cardiovascular Drugs ,(2010)
IM Macrae, Preclinical stroke research – advantages and disadvantages of the most common rodent models of focal ischaemia British Journal of Pharmacology. ,vol. 164, pp. 1062- 1078 ,(2011) , 10.1111/J.1476-5381.2011.01398.X
TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329
John A. Weigelt, Surgical Treatment: Evidence-Based and Problem-Oriented Journal of Trauma-injury Infection and Critical Care. ,vol. 51, pp. 1003- ,(2001) , 10.1097/00005373-200111000-00029
Wichittra Tassaneeyakul, Somsak Tiamkao, Thawinee Jantararoungtong, Pei Chen, Shu-Yi Lin, Wei-Hsuan Chen, Parinya Konyoung, Usanee Khunarkornsiri, Narong Auvichayapat, Kasemsin Pavakul, Kongkiat Kulkantrakorn, Charoen Choonhakarn, Siranun Phonhiamhan, Namfon Piyatrakul, Thiti Aungaree, Sunsanee Pongpakdee, Praphan Yodnopaglaw, Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population Epilepsia. ,vol. 51, pp. 926- 930 ,(2010) , 10.1111/J.1528-1167.2010.02533.X
Zaina P. Qureshi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, Kurt B. Stevenson, Sheryl L. Szeinbach, Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiology and Drug Safety. ,vol. 20, pp. 772- 777 ,(2011) , 10.1002/PDS.2155
May P. S. Lam, Bernard M. Y. Cheung, The pharmacogenetics of the response to warfarin in Chinese. British Journal of Clinical Pharmacology. ,vol. 73, pp. 340- 347 ,(2012) , 10.1111/J.1365-2125.2011.04097.X
David R. Bell, Rodney A. Rhoades, Medical physiology : principles for clinical medicine ,(1995)
E. Marshall, DRUG TRIALS: Violent Reaction to Monoclonal Antibody Therapy Remains a Mystery Science. ,vol. 311, pp. 1688- 1689 ,(2006) , 10.1126/SCIENCE.311.5768.1688